Literature DB >> 32387059

FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?

Josué de Moraes1, Timothy G Geary2.   

Abstract

Diseases caused by helminth infections affect more than a quarter of the population of the world, but the therapeutic arsenal is limited. The approval of moxidectin in 2018 and triclabendazole in 2019 by the FDA marked an important moment in the fight against diseases of poverty, such as helminthiases.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FDA; helminthiasis; moxidectin; triclabendazole

Year:  2020        PMID： 32387059     DOI： 10.1016/j.pt.2020.04.005

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN： 1471-4922


  8 in total

1.  Susceptibility of Angiostrongylus cantonensis Larvae to Anthelmintic Drugs.

Authors:  Daniel B Roquini; Gabriel L Silva; Leonardo L G Ferreira; Adriano D Andricopulo; Polrat Wilairatana; Josué De Moraes
Journal:  Front Pharmacol       Date:  2022-06-21       Impact factor: 5.988

2.  Therapeutic Effect of Diminazene Aceturate on Parasitic Blood Fluke Schistosoma mansoni Infection.

Authors:  Mariana G de Brito; Ana C Mengarda; George L Oliveira; Maria E Cirino; Tais C Silva; Rosimeire N de Oliveira; Silmara M Allegretti; Josué de Moraes
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 3.  High-content approaches to anthelmintic drug screening.

Authors:  Mostafa Zamanian; John D Chan
Journal:  Trends Parasitol       Date:  2021-06-03

Review 4.  Purinergic modulation of the immune response to infections.

Authors:  Natalia Eberhardt; Gastón Bergero; Yanina L Mazzocco Mariotta; M Pilar Aoki
Journal:  Purinergic Signal       Date:  2022-01-08       Impact factor: 3.765

Review 5.  Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors.

Authors:  Xavier Thuru; Romain Magnez; Hassiba El-Bouazzati; Gérard Vergoten; Bruno Quesnel; Christian Bailly
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

6.  Pharmacological characterization of novel heteromeric GluCl subtypes from Caenorhabditis elegans and parasitic nematodes.

Authors:  Nicolas Lamassiaude; Elise Courtot; Angélique Corset; Claude L Charvet; Cédric Neveu
Journal:  Br J Pharmacol       Date:  2021-12-27       Impact factor: 9.473

7.  N-(4-Methoxyphenyl)Pentanamide, a Simplified Derivative of Albendazole, Displays Anthelmintic Properties against the Nematode Toxocara canis.

Authors:  Taís C Silva; Ana C Mengarda; Bruna L Lemes; Susana A Z Lescano; Dalete Christine S Souza; João Henrique G Lago; Josué de Moraes
Journal:  Microbiol Spectr       Date:  2022-07-28

8.  Pyrazoline derivatives as promising novel antischistosomal agents.

Authors:  Cristiane S Morais; Ana C Mengarda; Fábio B Miguel; Karine B Enes; Vinícius C Rodrigues; Maria Cristina C Espírito-Santo; Abolghasem Siyadatpanah; Polrat Wilairatana; Mara R C Couri; Josué de Moraes
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.